糖生物學：全球診斷和治療市場

全球糖生物學市場規模預計將從 2022 年的 32 億美元增長到 2027 年的 53 億美元，在 2022-2027 年的預測期內以 11.1% 的複合年增長率增長。

治療行業預計將從 2022 年的 24 億美元增長到 2027 年的 41 億美元，同期復合年增長率為 11.2%。 診斷領域預計也將在 2027 年達到 12 億美元，高於 2022 年的 6.909 億美元，同期復合年增長率為 10.7%。

在本報告中，我們研究了全球糖生物學市場，並提供了市場概況、影響市場增長的各種因素的分析、相關法律法規、市場規模的變化和預測，以及每個細分市場和區域的詳細信息。分析、競爭格局、主要公司概況等。

內容

第一章介紹

第 2 章要點摘要

第三章市場動態

• 市場驅動力
• 市場製約因素
• 市場機會

第 4 章市場概述

• 概覽
  • 糖生物學
  • 聚醣的重要性
  • 聚醣功能及其生物學重要性
  • 聚醣的結構作用
  • 糖生物學研究的研究工具
  • 聚醣的結構分析
  • 作為糖生物學研究一部分的糖科學
  • 聚醣和糖綴合物的化學和□促合成
  • 用於糖生物學研究的生物信息學和數據庫資源
• 當前的市場趨勢
• 最近的戰略聯盟
• 新技術

第 5 章 COVID-19 對市場的影響

• 概覽
• COVID-19 引發的危機

第六章糖生物學治療藥物市場

• 概覽
  • 子類別
  • 治療性糖蛋白
  • 代謝性疾病的糖療法
  • 糖胺聚醣的治療應用
  • 基於碳水化合物的疫苗和聚醣作為疫苗成分
  • 抑制疾病中的聚醣識別
  • 抗糖抗體引起的輸血/移植排斥

第七章糖生物學診斷市場

• 概覽
  • 葡萄糖生物標誌物和自身免疫
  • 炎症性腸病中的葡萄糖生物標誌物
  • 針對特定神經病中的神經元聚醣的自身抗體
  • 心血管疾病中的糖生物學標誌物
  • 聚醣在阿爾茨海默病組織病理學中的作用
  • 葡萄糖生物標誌物與哮喘
  • 傳染病檢測中的糖生物標誌物
  • 基於糖生物學的生物標誌物和診斷測試的市場潛力
  • 基於糖生物學開發癌症生物標誌物和診斷試劑
  • 碳水化合物作為潛在的血清生物標誌物
  • 目前已上市的基於糖生物學的診斷劑
  • 擁有正在開發的糖生物學診斷平台和產品的公司
  • 基於糖生物學的診斷市場

第 8 章糖生物學試劑和工具市場

• 概覽
  • 分析和色譜技術
  • 聚醣陣列
  • 凝集素陣列
  • 糖生物學試劑盒
  • 糖生物學研究試劑
  • 碳水化合物：單醣、低聚醣和其他試劑

第 9 章市場細分：按地區

• 概覽
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第十章市場機會分析

• 波特的五力分析

第11章競爭格局

第12章公司簡介

• 主要公司
• AGILENT TECHNOLOGIES
• AMSBIO LLC
• BIO-TECHNE
• ISOSEP
• LUDGER LTD.
• MERCK KGAA
• NEW ENGLAND BIOLABS
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.
• WATERS CORP.

第 13 章附錄：縮寫詞

Highlights:

The global glycobiology market should reach $5.3 billion by 2027 from $3.2 billion in 2022 at a compound annual growth rate (CAGR) of 11.1% for the forecast period of 2022 to 2027.

Glycobiology therapeutics segment of the global glycobiology market is expected to grow from $2.4 billion in 2022 to $4.1 billion in 2027 at a CAGR of 11.2% for the forecast period of 2022 to 2027.

Glycobiology diagnostics segment of the global glycobiology market is expected to grow from $690.9 million in 2022 to $1.2 billion in 2027 at a CAGR of 10.7% for the forecast period of 2022 to 2027.

Report Scope:

The current report will provide an in-depth look at the glycobiology market. This report analyzes glycobiology market trends with data from 2021, estimates for 2022, projections of compound annual growth rates through 2027 (forecast period of 2022 to 2027), and regional market data. This report will highlight the current and future market potential of glycobiology along with providing a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints, and opportunities will be covered in the current report. The report also covers market projections for 2027 and indicates the market share for key market players.

The scope of the market in this report is segmented into glycobiology segment and region. The segments of glycobiology are: glycobiology therapeutics, glycobiology diagnostics, and glycobiology reagents and tools. The regional markets are North America, Europe, Asia-Pacific, and other world regions (Rest of the World). Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China, and India will be covered within their respective regional segments. For market estimates, data will be provided for 2021 as the base year, with forecasts for 2022 and 2027.

Report Includes:

• 51 tables
• An up-to-date overview and analysis of the global markets for glycobiology diagnostics and therapeutics
• Analyses of the global market trends, with historic revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Highlights of the market potential for glycobiology market, industry growth drivers, and areas of focus to forecast this market into various segments and subsegments
• Estimation of the actual market size and revenue forecast for global glycobiology market in USD million terms, and corresponding market share analysis by major market segments and region
• A look at new tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates
• Evaluation of promising candidates for carbohydrate-based diagnostics, drugs and vaccines
• Insight into how glycobiology offers enormous untapped potential in the discovery of new therapeutics derived from saccharides or other molecules which target the biosynthesis and function of saccharides
• Identification of leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
• Insight into recent industry structure for glycobiology diagnostics and therapeutics, current competitive scenario, clinical trials, ongoing research (R&D) activities, strategic alliances, and COVID-19 impact on the progress of this market
• Profile descriptions of the major market players, including Agilent Technologies Inc., Bio-Techne, Merck KGaA, Takara Bio Inc. and Waters Corp.

Table of Contents

Chapter 1 Introduction

• 1.1 Overview
• 1.2 Study Goals and Objectives
• 1.3 Reasons for Doing This Study
• 1.4 What's New in This Update?
• 1.5 Scope of Report
• 1.6 Information Sources
• 1.7 Methodology
• 1.8 Geographic Breakdown
• 1.9 Analyst's Credentials
• 1.10 BCC Custom Research
• 1.11 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Technological Advancements in the Analysis of Glycans
  • 3.1.2 Rising Prevalence of Chronic Disorders Globally
  • 3.1.3 Increasing R&D Investment by Pharma Companies
• 3.2 Market Restraints
  • 3.2.1 Challenges in Glycobiology
• 3.3 Market Opportunities
  • 3.3.1 Inorganic Strategies among Market Players

Chapter 4 Market Overview

• 4.1 Overview
  • 4.1.1 Glycobiology
  • 4.1.2 Significance of Glycan
  • 4.1.3 Function of Glycans and Their Biological Significance
  • 4.1.4 Structural Role of Glycans
  • 4.1.5 Research Tools for Glycobiology Studies
  • 4.1.6 Structural Analysis of Glycans
  • 4.1.7 Glycomics as Part of Glycobiology Research
  • 4.1.8 Chemical and Enzymatic Synthesis of Glycans and Glycoconjugates
  • 4.1.9 Bioinformatics and Database Resources for Glycobiology Research
• 4.2 Current Market Trends
  • 4.2.1 Protein and Glycan Glycoengineering
  • 4.2.2 Engineering Glycans and Glycan Mimics as Therapeutic Agents
  • 4.2.3 Glycobiology and Drug Delivery
  • 4.2.4 Oligosaccharide Libraries for Drug Discovery Research
  • 4.2.5 Glyconutrients as Therapeutics
• 4.3 Recent Strategic Alliances
• 4.4 Emerging Technologies
  • 4.4.1 Glycans in Medicine and Biotechnology
  • 4.4.2 Glycans in Nanotechnology, Bioenergy, and Materials Science

Chapter 5 Impact of COVID-19 on Market

• 5.1 Overview
• 5.2 COVID-19 Crisis
  • 5.2.1 Impact on Market for Glycobiology
  • 5.2.2 COVID-19 Measures

Chapter 6 Glycobiology Therapeutics Market

• 6.1 Overview
  • 6.1.1 Subcategories of Glycobiology Therapeutics
  • 6.1.2 Therapeutic Glycoproteins
  • 6.1.3 Glycan Therapeutic Approaches to Metabolic Diseases
  • 6.1.4 Therapeutic Applications of Glycosaminoglycans
  • 6.1.5 Carbohydrate-based Vaccines and Glycans as Vaccine Components
  • 6.1.6 Blocking Glycan Recognition in Diseases
  • 6.1.7 Transfusion and Transplantation Rejection by Anti-glycan Antibodies

Chapter 7 Glycobiology Diagnostics Market

• 7.1 Overview
  • 7.1.1 Glycobiomarkers and Autoimmunity
  • 7.1.2 Glycobiomarkers in Inflammatory Bowel Disease
  • 7.1.3 Autoantibodies Against Neuronal Glycans in Certain Neuropathies
  • 7.1.4 Glycobiology Markers in Cardiovascular Diseases
  • 7.1.5 Role of Glycans in the Histopathology of Alzheimer's Disease
  • 7.1.6 Glycobiomarkers and Asthma
  • 7.1.7 Glycobiomarkers in Infectious Disease Testing
  • 7.1.8 Market Potential for Glycobiology-based Biomarkers and Diagnostic Tests
  • 7.1.9 Glycobiology-based Cancer Biomarkers and Diagnostic Development
  • 7.1.10 Carbohydrates as Potential Serum Biomarkers
  • 7.1.11 Current Glycobiology-based Diagnostics on the Market
  • 7.1.12 Companies with Glycobiology Diagnostic Platforms and Products in Development
  • 7.1.13 Market for Glycobiology-based Diagnostics

Chapter 8 Glycobiology Reagents and Tools Market

• 8.1 Overview
  • 8.1.1 Analytical and Chromatography Techniques
  • 8.1.2 Glycan Arrays
  • 8.1.3 Lectin Arrays
  • 8.1.4 Glycobiology Kits
  • 8.1.5 Reagents for Glycobiology Research
  • 8.1.6 Carbohydrates: Monosaccharides, Oligosaccharides and Other Reagents

Chapter 9 Market Breakdown by Region

• 9.1 Overview
  • 9.1.1 North America
  • 9.1.2 Europe
  • 9.1.3 Asia-Pacific
  • 9.1.4 Rest of the World

Chapter 10 Analysis of Market Opportunities

• 10.1 Porter's Five Forces Analysis
  • 10.1.1 Threat of New Entrants
  • 10.1.2 Threat of Substitutes
  • 10.1.3 Bargaining Power of Suppliers
  • 10.1.4 Bargaining Power of Buyers
  • 10.1.5 Degree of Competition

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

• 12.1 Major Companies
• AGILENT TECHNOLOGIES
• AMSBIO LLC
• BIO-TECHNE
• ISOSEP
• LUDGER LTD.
• MERCK KGAA
• NEW ENGLAND BIOLABS
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.
• WATERS CORP.

Chapter 13 Appendix: Acronyms

List of Tables

• Summary Table : Global Market for Glycobiology, by Segment, Through 2027
• Table 1 : Global Diabetes Prevalence, Estimates and Projections, 2019-2045
• Table 2 : Cases of Diabetes Worldwide, by Type, 2019
• Table 3 : Global Prevalence of Diabetes, by Type, Through 2040
• Table 4 : Global HIV Epidemic, by Age Group, 2020
• Table 5 : Market Players: R&D Investment, 2019-2021
• Table 6 : Classification of Carbohydrates
• Table 7 : Examples of Glycosylation Deficiency and Their Pathological Effect
• Table 8 : Experimental Approaches to Studying Glycans
• Table 9 : Examples of Inhibitors/Modulators Used in Glycobiology Research
• Table 10 : Separation and Identification Techniques Used for Glycan Analysis
• Table 11 : Bioinformatics and Database Resources for Glycobiology Research
• Table 12 : Strategic Alliances in the Market for Glycobiology, 2020-2022
• Table 13 : Approved Glycobiology-related Treatments and Carbohydrate-based Drugs
• Table 14 : Global Market for Glycobiology Therapeutics, by Region, Through 2027
• Table 15 : Glycobiology-based Markers
• Table 16 : Global Death Share, by Various Cancer Types, 2015
• Table 17 : FDA-approved Cancer Biomarkers Currently Used in Clinical Practice
• Table 18 : Examples of Potential Glycoprotein Cancer Biomarkers
• Table 19 : Companies with Diagnostic Products in Development Based on Glycobiology Research
• Table 20 : Global Market for Glycobiology Diagnostics, by Region, Through 2027
• Table 21 : Companies Offering Glycobiology Reagents
• Table 22 : Global Market for Glycobiology Reagents and Tools, by Region, Through 2027
• Table 23 : Global Market for Glycobiology, by Region, Through 2027
• Table 24 : Diabetes Estimates in North America, by Country, 2000-2045
• Table 25 : Influenza Disease Burden, by Age Group, U.S., 2019 and 2020 Influenza Season
• Table 26 : North American Market for Glycobiology, by Country, Through 2027
• Table 27 : Diabetes Estimates in Europe, by Country, 2000-2045
• Table 28 : European Market for Glycobiology, by Country, Through 2027
• Table 29 : Tuberculosis Burden of Asian Countries, by Country, 2019
• Table 30 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
• Table 31 : Asia-Pacific Market for Glycobiology, by Country, Through 2027
• Table 32 : Diabetes Estimates in RoW, by Country, 2000-2045
• Table 33 : New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
• Table 34 : Porter's Five Forces Analysis: Glycobiology Market
• Table 35 : Agilent Technologies: Product Portfolio
• Table 36 : Agilent Technologies: Key Developments, 2016-2020
• Table 37 : AMSBIO LLC: Product Portfolio
• Table 38 : AMSBIO LLC: Key Developments, 2022
• Table 39 : Bio-Techne: Product Portfolio
• Table 40 : IsoSep: Product Portfolio
• Table 41 : Ludger Ltd.: Product Portfolio
• Table 42 : Ludger Ltd.: Key Developments, 2022
• Table 43 : Merck KGaA: Product Portfolio
• Table 44 : Merck KgaA: Key Developments, 2020 and 2021
• Table 45 : New England Biolabs: Insulin Product Portfolio
• Table 46 : Takara Bio Inc.: Product Portfolio
• Table 47 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 48 : Thermo Fisher Scientific Inc.: Key Developments, 2020
• Table 49 : Waters Corp.: Product Portfolio
• Table 50 : Acronyms Used in This Report

List of Figures

• Summary Figure : Global Market Shares of Glycobiology, by Segment, 2021
• Figure 1 : Emerging Glycomics Technologies
• Figure 2 : Cases of Diabetes Worldwide, by Type, 2019
• Figure 3 : Global Prevalence of Diabetes, by Type, 2018-2040
• Figure 4 : Numbers and Shares of New Cancer Cases, Women, 2020
• Figure 5 : Numbers and Shares of New Cancer Cases, Men, 2020
• Figure 6 : Schematic Presentation of O- and N-linked Glycans on Protein Receptor
• Figure 7 : Global Market for Glycobiology Therapeutics, 2019-2027
• Figure 8 : Global Market for Glycobiology Diagnostics, 2019-2027
• Figure 9 : Global Market for Glycobiology Reagents and Tools, 2019-2027
• Figure 10 : Global Market Shares of Glycobiology, by Region, 2021
• Figure 11 : North American Market Shares of Glycobiology, by Country, 2021
• Figure 12 : Cancer Diagnosis Share in Europe, by Gender, 2020
• Figure 13 : European Market Shares of Glycobiology, by Country, 2021
• Figure 14 : Asia-Pacific Market Shares of Glycobiology, by Country, 2021
• Figure 15 : Global Market Shares of Glycobiology, by Company, 2021
• Figure 16 : Agilent Technologies: Annual Revenue, 2019-2021
• Figure 17 : Agilent Technologies: Revenue Share, by Segment, 2021
• Figure 18 : Agilent Technologies: Revenue Share, by Region, 2021
• Figure 19 : Bio-Techne: Annual Revenue, 2019-2021
• Figure 20 : Bio-Techne: Revenue Share, by Business Segment, 2021
• Figure 21 : Bio-Techne: Revenue Share, by Region, 2021
• Figure 22 : Merck KGaA: Annual Revenue, 2019-2021
• Figure 23 : Merck KGaA: Revenue Share, by Business Segment, 2021
• Figure 24 : Merck KGaA: Revenue Share, by Region, 2021
• Figure 25 : Takara Bio Inc.: Annual Revenue, 2019-2021
• Figure 26 : Takara Bio Inc.: Revenue Share, by Segment, 2021
• Figure 27 : Takara Bio Inc.: Revenue Share, by Region, 2021
• Figure 28 : Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021
• Figure 29 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2021
• Figure 30 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2021
• Figure 31 : Waters Corp.: Annual Revenue, 2019-2021
• Figure 32 : Waters Corp.: Revenue Share, by Segment, 2021
• Figure 33 : Waters Corp.: Revenue Share, by Region, 2021